Studies from Hospital Clinic of Barcelona Yield New Data on Cytomegalovirus (At-Home Foscarnet Administration in Patients with Cytomegalovirus Infection Post-Allogeneic Stem Cell Transplantation: A Unicentric, Safe, and Feasible Program).

A study conducted at the Hospital Clinic of Barcelona in Spain examined the effectiveness and safety of at-home administration of the drug foscarnet (FCN) for patients with cytomegalovirus (CMV) infection post-allogeneic stem cell transplantation (allo-HCT). The study compared patients who received FCN in the hospital to those who received it at home and found that the proportions of patients with cured CMV infections were comparable between the two groups. The duration of FCN treatment and the occurrence of FCN toxicities were also similar between the two groups, except for hypocalcemia, which was more prevalent in the inpatient cohort. The study concluded that home administration of FCN is a safe, effective, and cost-efficient therapeutic option for patients with CMV infection and disease. [Extracted from the article]